

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-4 (Cancelled).

5 (Currently amended). The method according to claim 11, wherein the vascular endothelial growth factor (VEGF) inhibitor is selected from the group consisting of 3,7-dimethyl-1-propargylxanthine (DMPX), an A2-antagonist 7-(betahydroxyethyl) theophylline, 8-phenyltheophylline, the adenosine A2 receptor antagonist 8-(3-chlorostyryl) caffeine (CSC), theobromine, an antagonistic VEGF variant, soluble VEGF receptor sFLT-1, Tranilast, 8-(3-oxo-4,5,6-trihydroxy-3h-xanthen-9-yl)-1-naphthoic acid, suramin and platelet factor-4.

Claims 6-8 (Cancelled).

9 (Currently amended). A method for ~~reversibly~~ inhibiting ~~endothelial cell proliferation~~ angiogenesis in mammals, comprising administering to a subject a pharmaceutical composition, which comprises leptin, or a homologue or derivative thereof which retains activity substantially similar to wild type leptin, and optionally, an inhibitor of angiogenesis, in a

suitable dosage form and by a suitable route of administration to inhibit angiogenesis by inducing angiopoietin-2 (Ang-2).

Claim 10 (Cancelled).

11(Currently amended). The method of claim [[9]] 12, wherein the inhibitor of angiogenesis is a VEGF inhibitor.

12(New). The method of claim 9, wherein said pharmaceutical composition comprises an inhibitor of angiogenesis.

13(New). The method of claim 9, wherein said homologue has 80% sequence identity with the sequence of leptin.

14(New). The method of claim 9, wherein said homologue has 90% sequence identity with the sequence of leptin.

15(New). The method of claim 9, wherein said derivative has one or more chemical moieties attached to leptin.

16(New). The method of claim 15, wherein said one or more chemical moieties attached to leptin are water soluble polymers.

17(New). The method of claim 16, wherein said water soluble polymers are polyethylene glycol that form pegylated derivatives of leptin.

Appln. No. 10/070,295

Amd. dated July 12, 2006

Reply to Office Action of February 13, 2006

18(New). The method of claim 9, which inhibits angiogenesis in adipose tissue.